Possible new mechanisms of primary drug resistance in NSCLC with EGFR mutation treated with Osimertinib.

IUBMB Life · 2025 · PMC11796316 · PMID 39907312

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The serum oncological markers, including NSE, SCC, CYFRA21‐1, PROGRP, CA199, CA242, CA50, and CA724, fluctuated, but all showed an increasing trend since July 2022.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.